- Algernon Pharmaceuticals Inc. (AGN) receives notice of allowance for Ifenprodil patent application for idiopathic pulmonary fibrosis treatment (IPF)
- The company has also filed corresponding patent applications in the U.S., Europe, China, and Japan
- Ifenprodil prevents the signaling of receptors that cause disorders such as schizophrenia, Alzheimer’s, and other neurodegenerative diseases
- The company claims Ifenprodil can treat forming lung diseases, including IPF
- Algernon Pharmaceuticals Inc. (AGN) is up 2.21 per cent trading at $7.85 per share as of 12:13 p.m. EST
Algernon Pharmaceuticals Inc. (AGN) receives notice of allowance for Ifenprodil patent application for idiopathic pulmonary fibrosis treatment (IPF).
Algernon is a clinical-stage pharmaceutical development company based in Canada
The company has also filed corresponding patent applications in the U.S., Europe, China, and Japan.
Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B).
Ifenprodil prevents the signalling of receptors that cause disorders such as schizophrenia, Alzheimer’s, and other neurodegenerative diseases.
The N-methyl-D-aspartate (NMDA) receptor is found on many tissues including lung cells, T-cells, neutrophils, and certain types of cancer cells.
The company claims Ifenprodil can treat forming lung diseases, including IPF.
Algernon’s strategy for its repurposed drug program includes protecting its compounds by filing patent applications.
This includes those for novel salt forms, method of use, dosing, and formulation.
Algernon is currently conducting a proof-of-concept 20 patient Phase 2 human trial.
It will determine the efficacy of Ifenprodil in the preservation of lung function in IPF patients and its associated cough.
Ifenprodil has been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a mouse model of IPF.
In addition, Ifenprodil significantly reduced cough frequency and delayed onset in a guinea pig acute cough model.
Algernon Pharmaceuticals Inc. (AGN) is up 2.21 per cent trading at $7.85 per share as of 12:13 p.m. EST.
